The pharmaceutical industry is under constant pressure to evolve, driven by advancements in drug development, regulatory changes, and increasing consumer expectations. A critical, yet often overlooked, aspect of this evolution is the secondary packaging of sterile injectable drugs. Secondary packaging, which encompasses the outer packaging protecting the primary container, plays a pivotal role in ensuring drug integrity, facilitating user handling, and communicating essential information. However, the design of secondary packaging for sterile injectables faces a myriad of contemporary challenges, particularly in balancing sustainability with end-user needs. Artificial Intelligence (AI) offers promising solutions to these challenges, potentially revolutionizing how these crucial packaging components are designed and implemented.

The 21st century has ushered in an era of unprecedented technological advancement, particularly within the realm of biological sciences. Among the most transformative developments has been the rise of “omics” technologies, each offering a unique lens through which to view the intricate machinery of life. From genomics, which deciphers the DNA blueprint, to transcriptomics, which measures gene expression, and proteomics, which catalogues the protein repertoire, these individual omics layers have provided invaluable insights into biological processes. However, a growing excitement now surrounds the convergence of these technologies into what is known as “multiomics,” an integrative approach that promises to revolutionize our understanding of biological systems and pave the way for personalized medicine and targeted therapies.